The aim of the current study was to assess the direct effect of protamine on conventional thrombelastography in vitro. Protamine was added to blood samples collected from 25 adult cardiac surgical patients prior to the induction of anaesthesia and after separation from cardiopulmonary bypass. The final protamine concentrations were 0 (control), 0.05 mg/ml, 0.1 mg/ml and 0.2 mg/ml (i.e. sufficient to reverse heparin 0, 5, 10 and 20 IU/ml respectively, assuming a 1:1 reversal ratio). In the pre-induction samples, protamine was associated with increases in r time and reductions in maximum amplitude (P<0.01). After bypass, the control samples demonstrated a heparin effect as expected, which was corrected by the addition of protamine 0.05 mg/ml. However, the higher concentrations of protamine were again associated with increases in r time and reductions in maximum amplitude (P<0.01). The results indicate that protamine has a direct anticoagulant effect on conventional thrombelastography in vitro. This effect occurs whether protamine is present alone, or whether protamine is present in excess after neutralization of heparin. Unless this effect is taken into account, excess protamine may confound the interpretation of conventional thrombelastography in cardiac surgical patients.
Thrombelastography (TEG) is frequently used to assess coagulation in cardiac surgical patients, particularly after cardiopulmonary bypass (CPB) [1] [2] [3] . Most of these patients receive large doses of protamine to reverse heparin anticoagulation. The amount of protamine is usually tailored to the amount of heparin used, in order to avoid protamine excess. However, due to variability in heparin and protamine pharmacokinetics between patients, it may not be possible to prevent excess protamine in all cases 4 . Excess protamine has direct anticoagulant effects of its own 4 . This has been demonstrated using several techniques, including the activated clotting time (ACT) 5 and modified TEG using the Rotem ® (Pentapharm, Munich, Germany) 6 . It is possible that excess protamine also affects conventional TEG, which would confound its interpretation. For example, an anticoagulant effect on the TEG caused by excess protamine could be interpreted as a deficiency of coagulation factors or residual heparin, possibly leading to inappropriate therapy. At present, the direct effects of excess protamine on conventional TEG, if any, are not known. The aim of the current study was to assess the direct effect of protamine on conventional TEG in vitro, using blood from cardiac surgical patients, before and after CPB.
METHODS
With institutional ethics approval and informed consent, blood samples were obtained from 25 adult patients undergoing elective cardiac surgery requiring CPB. None of the patients had received aspirin or other non-steroidal anti-inflammatory drugs for at least 72h prior to surgery, or clopidogrel for at least one week prior to surgery. All patients received preoperative deep venous thrombosis (DVT) prophylaxis with unfractionated porcine heparin 5000IU sc on the evening before surgery and on the morning of surgery (≥2h pre-operatively). Patients also received their regular antihypertensive and anti-anginal medication, which varied among patients, but often included β-adrenergic receptor antagonists, calcium channel antagonists, angiotensin converting enzyme inhibitors and nitrates.
Anaesthetic management was similar for all patients. Anaesthetic premedication consisted of lorazepam 2-3 mg po two hours preoperatively and morphine 0.15 mg/kg intramuscularly with promethazine 25 mg IM one hour preoperatively. Anaesthetic induction was with midazolam 0.05 mg/kg intravenously (IV), fentanyl 10-15 μg/kg IV and propofol up to 1 mg/kg IV. Pancuronium was used for muscle relaxation. anaesthesia was maintained with isoflurane 1.0 to 2.0% in oxygen enriched air and boluses of fentanyl 250-500 μg IV.
The CPB circuit included a roller pump, membrane oxygenator and arterial filter, with a 2.3 litre crystalloid prime. Anticoagulation was achieved with unfractionated porcine heparin 3 mg/kg IV, with an additional 100 mg in the pump prime. Further doses of heparin, 50 to 100 mg IV were given as necessary during CPB to maintain the kaolin activated clotting time (ACT) (Hemochron 401, Edison, NJ, U.S.A.) greater than 480s.
Blood samples were collected for TEG analysis (TEG 5000, Haemoscope, Niles, IL, U.S.A.) prior to the induction of anaesthesia and after separation from CPB. The pre-induction blood samples were collected from a non-heparinized arterial cannula using a two-syringe technique. The first syringe was used to remove the dead space volume (5 ml). This was returned to the patient via a peripheral venous cannula in a sterile manner. A second syringe was used to collect a 4 ml sample for TEG analysis. The post-CPB samples (4 ml) were collected from residual blood in the CPB reservoir. Scavenging of blood from the patient to the venous reservoir ceased prior to the systemic administration of protamine.
The blood from each sample was divided equally into four 1.0 ml vials containing kaolin activator (Haemoscope, Niles, IL, U.S.A.). Twenty μl of normal saline was added to the control vial. Three protamine solutions were prepared (Aventis Pharma, Lane Cove, N.S.W., Australia); 10 mg/ml (undiluted), 5 mg/ml (diluted 1:1 with normal saline) and 2.5 mg/ml (diluted 1:3 with normal saline). Twenty μl of the 2.5 mg/ml solution was added to the first test vial (final concentration 0.05 mg/ml). similarly, 20 μl of the 5 mg/ml and 10 mg/ml solutions were added to the other two vials (final concentrations 0.1 mg/ml and 0.2 mg/ml).
in this way, the final protamine concentrations in the test vials (0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml) were sufficient to reverse heparin 5, 10 and 20 IU/ml, assuming a 1:1 reversal ratio 4 .
Thrombelastographs were then performed simultaneously on blood samples (0.35 ml) from all four vials according to the manufacturer's instructions. This was achieved using two two-channel TEGs connected to one computer and display. Each of the four TEG channels was calibrated daily. The channels used for the control and test samples were varied between patients in a random manner. Each TEG was run for up to 120 min. The r time and maximum amplitude (MA) for each run was recorded. If the r time was >60 min, an MA value of zero was used.
For the pre-induction samples, the protamine 0.05 mg/ml r and MA values were compared to the control using one-tailed paired t tests. Similarly, the protamine 0.1 mg/ml values were compared to the 0.05 mg/ml values, and the 0.2 mg/ml values were compared to the 0.1 mg/ml values. This was repeated for the post-CPB samples (with the exception of the control MA which equalled zero in all samples due to the heparin effect). Due to the multiple simultaneous comparisons, only P values <0.01 were considered significant. all statistical analyses were performed using Microsoft Excel data analysis software (version 11.0, Microsoft Corporation, U.S.A.).
The k time and α angle data were not statistically analysed, in part because they are not wholly independent of the MA, and in part to limit the number of statistical comparisons performed.
REsuLTs
The patients from whom blood samples were taken (n=25) had a mean age of 60 years (range 35-85y) and a mean weight of 85 kg (range 60-118 kg). They included 21 males and four females. The mean pre-induction platelet count was 225× 10 9 /l (range 159-345×10 9 /l). The mean total dose of heparin administered before or during CPB was 500 mg (range 310-710 mg). The mean duration of CPB was 94 min (range 54-152 min). The mean final aCT prior to separation from CPb was 612s (range 465-1140s).
The pre-induction blood samples from three patients were excluded from analysis due to abnormal control r times consistent with a heparin effect. These three patients had a mean age of 66y, mean weight of 91 kg and a mean platelet count of 185×10 9 /l. The r times from their 'control' vials were 31 min, 43 min and 92 min. These were corrected to 11.9 min, 15.1 min and 17.4 min respectively in their protamine 0.05 mg/ml vials.
The remaining patients (n=22) had pre-induction control r time and MA within the normal range. However, all the protamine containing samples had mean r times outside the normal range. TEG traces from a typical patient are shown in Figure 1 . The protamine 0.05 mg/ml samples had a longer r time than the control (29.1±13 min vs 6.1±2 min, mean SD, P<0.0001, Figure 2) . Similarly, the protamine 0.1 mg/ml sample had a longer r time than the 0.05 mg/ml sample (45±22 min vs 29.1±13 min, P<0.0001, Figure 2 ) and the protamine 0.2 mg/ml sample had a longer r time than the 0.1 mg/ml sample (79.6±29 min vs 45± 22 min, P<0.001, Figure 2 ).
Protamine also reduced the MA, but the effect was less marked than on r time ( Figure 3 ). With the pre-induction samples, protamine 0.05 mg/ml was associated with a reduction in MA vs control (51.9±16 mm vs 65.4±9 mm, P<0.0001, Figure 3) .
Similarly, the protamine 0.1 mg/ml sample had a smaller MA than the 0.05 mg/ml sample (39±20 mm vs 51.9±16 mm, P=0.0018, Figure 3 ) and the protamine 0.2 mg/ml sample had a smaller MA than the In contrast, the r time and MA in the protamine 0.05 mg/ml samples were relatively normal (9.3± 7 min, 63±7 mm respectively). The protamine 0.1 mg/ ml sample was again associated with a longer r time than the 0.05 mg sample (20.7±14 min vs 9.3±7 min P<0.0001, Figure 5) . Similarly, the 0.2 mg/ml sample was associated with a longer r time than the 0.1 mg/ml sample (37±28 mm vs 20.7±14 min, P<0.001, Figure  5 ). Post CPB, the protamine 0.1 mg/ml sample had a slightly smaller MA than the 0.05 mg/ml sample (57±13 mm vs 63±7 mm, P=0.0047, Figure 6 ) and the protamine 0.2 mg/ml sample had a slightly smaller MA than the protamine 0.1 mg/ml sample (45±25 mm vs 57±13 mm, P=0.002, Figure 6 ).
DISCUSSION
The results indicate that protamine has a direct anticoagulant effect on conventional TEG in vitro. This effect occurs whether protamine is present 
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alone, or whether protamine is present in excess, after neutralization of heparin. The effect is present at concentrations that may be found clinically and increases further with higher concentrations. Unless this effect is taken into account, excess protamine may confound the interpretation of the TEG in cardiac surgical patients.
While this study was performed in vitro, it is likely that its findings and implications would be similar in vivo. Protamine does not require biotransformation for its pharmacological effects 7 , so its effects on blood in vivo should be the same as its effects on similar blood in vitro. The concentrations studied covered a wide range, from an expected therapeutic concentration through to substantial excess. For example, the amount of protamine required to neutralize heparin is about 0.01 mg protamine per unit of heparin 4 . During CPB, the target heparin level is in the range of 2-4 IU/ml 8 . Therefore, a protamine concentration of 0.05 mg/ml should neutralize all the heparin present in blood collected at the end of a CPB run. This concentration may be considered 'therapeutic' for the purposes of neutralizing heparin post-CPB. Protamine 0.1 mg/ml would represent twice the concentration necessary, or an excess of 0.05 mg/ml. This degree of excess could occur clinically, because higher doses of protamine (up to 2 mg per mg of heparin administered) are used occasionally 4 . In contrast, protamine concentrations 0.1-0.2 mg/ml are unlikely to be encountered clinically, and were included only to assess the theoretical effects of substantial protamine excess.
The effect of protamine on r time was more marked than on MA. Protamine 0.05 mg/ml in the pre-induction samples more than doubled the r time, but reduced the MA by only about 20%. This relatively greater effect on r time vs MA was observed with other concentrations of protamine in the preinduction samples and protamine excess in the post-CPb samples. This finding suggests that protamine has a greater effect on fibrin formation than on platelet aggregation, because the r time is an index of the time to onset of fibrin formation, while the Ma is an index of clot strength (which in turn depends on the interaction between fibrinogen and platelets) 9 .
Several previous studies have demonstrated an anticoagulant effect of protamine 4-6,10-12 . For example, Mochizuki et al showed that protamine to heparin ratios >1.3:1 in vitro prolong the ACT and reduce ADP-induced platelet aggregation 5 . They recommended that more specific tests than the aCT be used to assess coagulation in the presence of bleeding post-CPB 5 . They emphasised that failure to appreciate the effects of excess protamine on the ACT may lead to inappropriate therapy, including the administration of further protamine unnecessarily.
While the anticoagulant and antiplatelet effects of protamine are well recognised, protamine does not prolong all coagulation tests. For example, Perhash found that protamine 0.3-1.0 mg/ml produced marked prolongations of both the activated partial thromboplastin time (APTT) and prothrombin time (PT), but the thrombin time (TT) was shortened 12 . The relative lack of effect of protamine on TT persisted with higher protamine concentrations (1-2 mg/ml). Therefore, it cannot be assumed that protamine will prolong all coagulation tests and the effects of protamine on each test must be assessed individually.
More recently, Mittermayr et al assessed the effects of heparin and protamine on modified TEG in vitro using the Rotem ®6 . They found that protamine 0.1-1.6 u/ml produced significant increases in coagulation time (CT) in thromboplastin-phospholipid containing samples (INTEM), but not in tissue factor containing samples (EXTEM). It is not possible to directly compare our findings to those of Mittermayr et al. Firstly, neither thromboplastin-phospholipid nor tissue factor is present in conventional TEG. secondly, Mittermayr et al used recalcified citrated blood samples from healthy volunteers, rather than fresh whole blood from cardiac patients. Moreover, Mittermayr et al assessed a lower range of protamine concentrations. Nevertheless, our findings were not dissimilar, in that both studies identified a significant dose-related anticoagulant effect of protamine in vitro.
The mechanism involved in the anticoagulant effect of protamine has not been fully elucidated, but appears to involve several processes 10, 11 . Protamine is known to precipitate fibrinogen and fibrin monomer 10 , and also reversibly inhibits thrombin, and the inactivation of thrombin by antithrombin III 11 . In any event, it is recognised that protamine is a much weaker anticoagulant than heparin 13 . This is supported by the data in this study. For example, protamine 0.2 mg/ml (4× 'therapeutic' concentration) did not produce as marked an anticoagulant effect as residual heparin in the CPB reservoir (anticipated to be 2-4 IU/ml).
The sensitivity of the TEG to extremely small concentrations of heparin was highlighted by the prolonged r times in the pre-induction samples from three patients. This effect was reversed by the addition of protamine in all three patients, effectively confirming that this was a heparin effect. Presumably, this greater than expected 'heparin effect' in these patients could be explained by variability in heparin absorption or disposition following the administration of unfractionated heparin 5000 IU sc 2h preoperatively. This finding is cause for concern, given that similar heparin thromboprophylaxis is given to a large number of patients who go on to receive central neuraxial blockade preoperatively.
Protamine also affects platelet function, although again the exact mechanism is not known [14] [15] [16] . It appears that the heparin-protamine complex may have a greater effect on platelet aggregation in response to ADP than protamine alone 14 . However, protamine alone has been shown to reduce platelet aggregation in response to thrombin 15 . Protamine neutralization of heparin has been shown to reduce P selectin expression after exposure to thrombin receptor agonist peptide (TRaP) 16 . Our results suggest that protamine has only modest effects on platelet function as assessed by the TEG. In fact, the reduction in MA could be explained by the known effect of protamine on fibrinogen 17 . However, it is recognised that conventional TEG is a relatively insensitive index of platelet function, and that no conclusions about the effect of protamine on platelets can be made on the basis of this study 18, 19 .
During CPB, the target ACT is usually about 480-600s, which equates to a heparin level of about 2-4 IU/ml 8 . The heparin dose required to obtain this level is about 3 mg/kg 8 . Ideally, the dose of protamine used to reverse the heparin should be based on the actual heparin level 4 . In practice, because the measurement of heparin level is not routinely performed, the protamine dose is usually empirical and based on the amount of heparin administered. A common protamine dose is 1 to 1.3 mg per mg of heparin administered, which should fully reverse all heparin present 4 . Unfortunately, despite the administration of an apparently adequate dose of protamine, coagulation may occasionally remain impaired. In this situation a common initial response is to give additional protamine to exclude residual heparin as a cause. This may be inappropriate if there is no residual heparin.
The ACT is the most common test to assess heparin effect. however, the aCT is not specific for heparin, and there may be several other causes for impaired coagulation, including protamine excess 5, 20 . The TEG is another test used to assess coagulation in cardiac surgical patients, particularly if the development of a coagulopathy is suspected. The main advantage of TEG is that it provides a global assessment of coagulation, including fibrin formation, clot strength and fibrinolysis 9 . It also provides some indication of platelet function, although it is relatively insensitive to the effects of many anti-platelet drugs 18, 21 . The finding of a prolonged r time post-CPb may suggest residual heparin or clotting factor deficiency. The results of this study indicate that protamine excess may be another cause. Therefore, when there is doubt about the presence of residual heparin, a more specific assessment for the presence of residual heparin should be undertaken. This can be achieved by comparing ACT or TEG responses with and without the addition of heparinase 6, 20, 22, 23 .
TEG cups with pre-added heparinase are available for use during CPB (Haemoscope, Niles, IL, U.S.A.). The added heparinase removes any heparin effect and thus allows coagulation assessment prior to separating from CPB. Spiess et al have suggested that the addition of protamine to TEG cups ex vivo is a suitable and less expensive alternative, so long as a correct concentration of protamine is used 24 . The current results reinforce the need to avoid protamine excess if protamine is used for this purpose.
While the aim of this study was to assist in the interpretation of the TEG in cardiac surgical patients, our findings may have implications for protamine dosing post-CPb. if our findings were to apply in vivo, they would suggest that excess protamine has real anticoagulant effects that may contribute to increased bleeding post-CPB. This would support the finding of Mochizuki et al that excess protamine prolongs the ACT and the practice of giving excess protamine on an empirical basis may be harmful 5 . however, our findings also support previous studies that have shown that the anticoagulant effects of protamine are less than heparin. For this reason, a small protamine excess might be preferable to a small heparin excess. Fortunately, the half-life of protamine is relatively short, so any effect of excess protamine on coagulation would be short-lived 25 . Clearly, the most appropriate approach if residual heparin is suspected is to measure the heparin level, or compare samples with and without the addition of heparinase. if these more specific diagnostic techniques are not available, any supplementary protamine should be given in small increments, with frequent reassessment of the coagulation status. While a normal TEG in this situation indicates satisfactory neutralization of heparin, a prolonged r time will not distinguish between a large protamine excess and a small heparin excess.
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